Sidley is representing Tempest Therapeutics, Inc., a privately-held, clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted and immune-mediated mechanisms, in its merger with Millendo Therapeutics, Inc., in an all-stock transaction.  See more information here.

See all Member News